7 terminated, 5 completed, 4 recruiting, 2 active not recruiting. 22 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Terminated 7, Completed 5, Recruiting 4, Active not recruiting 2, Unknown 2, Suspended 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 3, Terminated 3, Withdrawn 1 |
Follow Advanced Accelerator Applications: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 10 | 2026-06-30 | 2026-06-05 |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer 177Lu-PSMA-617 - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 48 | 2026-04-07 | 2026-06-04 |
| Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer [177Lu]Lu-PSMA-617, Ipilimumab - Very High Risk Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | University Hospital, Essen | 1 | 2025-08-25 | 2026-03-13 |
| Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in 77 Lu-DOTA0-Tyr3-Octreotate - Metastatic Nasopharyngeal Cancer | Phase 2 | Suspended | National Cancer Centre, Singapore | 25 | 2023-05-05 | 2026-05-22 |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Lutetium [177Lu] oxodotreotide/dotatate - Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma | Phase 2 | Active not recruiting | Advanced Accelerator Applications | 11 | 2022-08-31 | 2026-02-12 |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC 177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 93 | 2022-04-29 | 2023-12-15 |
| Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection - Neuroendocrine Tumor, Liver Metastases | Phase 2 | Recruiting | University Hospital, Bordeaux | 23 | 2021-09-24 | 2025-07-23 |
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma 177Lu-DOTATATE - Neuroblastoma Recurrent, Neuroblastoma | Phase 2 | Recruiting | Jakob Stenman | 24 | 2021-05-19 | 2026-11-09 |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome | Phase 2 | Unknown | King's College Hospital NHS Trust | 20 | 2020-10-01 | 2020-08-04 |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma | Phase 1 / Phase 2 | Withdrawn | Sue O'Dorisio | 2020-08-04 | 2021-06-08 | |
| Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer 177Lu-PSMA-617 - Prostate Cancer | Phase 2 | Completed | Radboud University Medical Center | 58 | 2020-07-20 | 2026-02-27 |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy 177Lu-PSMA-617, Docetaxel - Metastatic Hormone Naive Prostate Cancer | Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 130 | 2020-04-21 | 2025-07-11 |
| [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake [177Lu]-NeoB, [68Ga]-NeoB, LCZ696 - Neoplasms | Phase 1 / Phase 2 | Completed | Advanced Accelerator Applications | 35 | 2019-07-24 | 2026-07-28 |
| [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) [68Ga]-NeoBOMB1 - Breast Cancer, Prostate Cancer | Phase 2 | Terminated | Advanced Accelerator Applications | 19 | 2018-07-03 | 2020-10-23 |
| 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) [68Ga]-PSMA-R2 - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Completed | Advanced Accelerator Applications | 30 | 2018-05-23 | 2020-11-17 |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate - Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Completed | Georgetown University | 9 | 2017-11-20 | 2021-03-16 |
| 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis rhAnnexin V-128 - Spondyloarthritis | Phase 2 | Terminated | Advanced Accelerator Applications | 5 | 2017-09-18 | 2019-12-13 |
| 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer 99mTc-rhAnnexin V-128 - Breast Cancer, Doxorubicin Induced Cardiomyopathy | Phase 2 | Terminated | Advanced Accelerator Applications | 14 | 2016-11-02 | 2020-12-11 |
| 99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis 99mTc-rhAnnexin V-128 - Carotid Artery Plaque | Phase 2 | Terminated | Advanced Accelerator Applications | 39 | 2016-06-23 | 2020-10-09 |
| Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis 99mTc-Annexin V-128 SPECT - Endocarditis, Thrombosis | Phase 1 / Phase 2 | Terminated | Institut National de la Santé Et de la Recherche Médicale, France | 11 | 2016-02-05 | 2021-08-26 |
Showing 20 of 22. Sign in to see all of them.
Neoplasms (4) · Prostatic Neoplasms (4) · Breast Neoplasms (3) · Genital Neoplasms, Male (2) · Neoplasms by Site (2) · Neuroendocrine Tumors (2) · Paraganglioma (2) · Pheochromocytoma (2) · Prostatic Diseases (2) · Small Cell Lung Carcinoma (2) · Spondylitis, Ankylosing (2) · Urogenital Neoplasms (2) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Carcinoid Heart Disease (1)
lutetium Lu 177 dotatate (7) · Pluvicto (4) · Ipilimumab (2) · Nivolumab (2) · Biopsy (1) · Docetaxel (1) · Ga(III)-DOTATOC (1) · Injections (1) · Lutetium (1) · Lutetium-177 (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · Sunitinib (1) · Valsartan (1) · copper dotatate CU-64 (1)
France (7) · United States (7) · Netherlands (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Canada (2) · Cyprus (1) · Denmark (1) · Germany (1) · Lithuania (1) · Norway (1) · Poland (1) · Singapore (1)
Arun Azad, MBBS PhD FRACP (1) · Chul Kim, MD (1) · Daniel Tan, BSc, MBBS, PhD (1) · Dominique Le Guludec, MD, PhD (1) · Emmanuel Seront, MD (1) · Jakob Stenman, MD PhD (1) · James Nagarajah, Prof. (1) · John Prior, MD, PhD (1) · M. Sue O'Dorisio, MD, PhD (1) · Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS (1) · Rodney F Pommier (1) · Shahneen Sandhu, MBBS, FRACP (1)
PMID 32616557, PMID 32928177, PMID 33189510, PMID 34736509, PMID 35359899, PMID 38753757, PMID 39293461, PMID 39915126, PMID 40198358, PMID 41073165, PMID 41926960, PMID 42225102
2023 (2), 2017 (1)